Konsume
Interval Day Week Month
Newswire Search Past 90 Days 13 stories 8 Publishers
Trending Today
Sort By: Snapshot
Buzz
Media Coverage
World View

Related Topics
Topic # Mentions Topic Reach
stock rises3-
the3-
ivonescimab3-
Prominent Journalists
Byline Articles Written Avg Reach
RTTNews Staff Writer 3 -
By Salong Debbarma 2 -
Meghana Keshavan 1 -
Frank Vinluan 1 -
Gayathry Prakash 1 -
Irene Madongo 1 -
by PR Newswire 1 -
Bridget Bennett 1 -
Prabha Kurup 1 -
Amy Johnson LLB Finance Reporter 1 -


Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts

Bridget Bennett — marketbeat.com


Lunit And Summit Collaborate On AI-Powered Biomarker Discovery For Ivonescimab

Gayathry Prakash — rttnews.com


Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development – Thailand Business News

by PR Newswire — thailand-business-news.com


Summit Therapeutics Stock Rises 7% Over Initiation Of Global Phase II Study Of Ivonescimab

RTTNews Staff Writer — rttnews.com


AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug

Frank Vinluan — medcitynews.com


AstraZeneca invests $2 billion in Summit Therapeutics

Meghana Keshavan — statnews.com


AstraZeneca To Inject $2B In US Cancer Biopharma

Irene Madongo — law360.com


AstraZeneca invests $2b in Summit Therapeutics to accelerate cancer drug development - London Business News

Amy Johnson LLB Finance Reporter — londonlovesbusiness.com


AstraZeneca to invest $2bn in Summit for ADC combination therapies

By Salong Debbarma — pharmaceutical-business-review.com


Summit Therapeutics (SMMT): Time To Take A Look Ahead Of The FDA Decision

Prabha Kurup — rttnews.com

Execution: 3.04 Seconds. 31.82 mb used.